These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15794390)

  • 1. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.
    Pulicken M; Bash CN; Costello K; Said A; Cuffari C; Wilterdink JL; Rogg JM; Mills P; Calabresi PA
    Mult Scler; 2005 Apr; 11(2):169-74. PubMed ID: 15794390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
    Jeffery DR; Chepuri N; Durden D; Burdette J
    Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
    Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
    Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL;
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
    Smith DR; Weinstock-Guttman B; Cohen JA; Wei X; Gutmann C; Bakshi R; Olek M; Stone L; Greenberg S; Stuart D; Orav J; Stuart W; Weiner H
    Mult Scler; 2005 Oct; 11(5):573-82. PubMed ID: 16193896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
    Gottesman MH; Friedman-Urevich S
    Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
    Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
    Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together.
    Messori A; Fadda V; Maratea D; Trippoli S
    J Neurol Sci; 2014 Dec; 347(1-2):408-10. PubMed ID: 25455308
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-β or azathioprine as add-on therapies in patients with active multiple sclerosis.
    Ticha V; Kalincik T; Havrdova E
    Neurol Res; 2012 Dec; 34(10):923-30. PubMed ID: 22910063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?
    Durelli L; Oggero A; Verdun E; Isoardo G; Ricci A; Barbero P; Bergamasco B
    J Neurol Sci; 2000 Sep; 178(1):37-41. PubMed ID: 11018247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS.
    Calabresi PA; Wilterdink JL; Rogg JM; Mills P; Webb A; Whartenby KA
    Neurology; 2002 Jan; 58(2):314-7. PubMed ID: 11805267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.